Skip to content

ERIS-ErisLifesciencesLtd

Research

Eris | Power of Empathy Eris Lifesciences Ltd. Live Share Price Today, Stock Analysis and Scores, Ratings, Estimates, Financials

[!info]- ERIS.NS Name: Eris Lifesciences Limited Currency: INR Volume: 76,848 Market cap: 123.581B Day range: 897 – 922.1 52W range: 551.3 – 971.9

Fri Dec 29 2023 01:54:18 GMT+0530 (India Standard Time)

Strength

  • Buying up brands from biocon.
  • matching sales estimates and growing

Products

Eris Lifesciences Ltd. is a pharmaceutical company that develops, manufactures, and sells medicines that treat both long-term and short-term illnesses 1 . The company’s product portfolio includes tablets, capsules, sprays, syrups, drops, powder, injections, cookies, ointments, and soft gels to treat pain, diabetes, cardiovascular, gynecological, respiratory, neurological, and gastrointestinal disorders 2 . They also sell nutrition formulations, vitamins, and minerals 2 . Some of their leading brands include Glimisave, Tendia, Cyblex, Eritel, Olmin, and LNBloc 3 .

Sectors

Eris Lifesciences Ltd. operates in the Pharmaceuticals sector, with a focus on chronic and acute therapy segments 4 . The company provides a wide range of products in chronic and acute therapy segments which includes capsules, tablets, and sachets 5 . They have established a leading presence in their core cardio-metabolic franchise 6 .

Management

The management team of Eris Lifesciences Ltd. includes Mr. Amit Bakshi (Chairperson & Managing Director), Mr. Inderjeet Singh Negi (Executive Director), Ms. Kalpana Unadkat (Independent Director), Mr. Kaushal Shah (Executive Director), Mr. Krishnakumar Vaidyanathan (COO & Executive Director), Mr. Milind Talegaonkar (Co. Secretary & Compl. Officer), Mr. Prashant Gupta (Independent Director), Mr. Rajeev Dalal (Independent Director), Mr. Sachin Shah (Chief Financial Officer), and Mr. Vasudevan Sujesh (Independent Director) 7 .

Capacity

Eris Lifesciences Ltd. operates with over 4000 employees working out of their corporate offices in Ahmedabad and Mumbai, the field, and their Guwahati facility 8 . The manufacturing plant can operate up to a maximum of three shifts per day 9 .

Growth

Eris Lifesciences Ltd. has shown significant growth in recent years. The company reported that their revenue for the third quarter of FY23 climbed by 27 percent year-on-year (YoY) to a total of Rs 420 crore 1 . The company has built multiple levers for growth in the branded generics space by broadening its dermatology portfolio through acquisitions, adding Insulin and its analogs in the anti-diabetes segment, maintaining an uptick in DPP4/SGLT2 sales, leveraging patient care platform and specialist engagement, and adding medical representatives to increase reach 1 .

Acquisition into the nephro space by buying out business units from Biocon

Challenges

In the wake of the global pandemic, Eris was faced with 2 primary challenges: ensuring the safety of its employees, customers, and vendors as well as ensuring continuity of business to serve doctors and patients 10 . The company also faces challenges due to increasing competition in the pharmaceutical industry 11 .